论文部分内容阅读
[目的]观察曲昔派特治疗慢性胃炎的疗效。[方法]将慢性胃炎患者随机分为治疗组与对照组,各60例。治疗组用曲昔派特(100mg/次,tid,餐后服用),对照组用迪乐(110mg/次,qid,餐前及睡前服用),2组疗程均为4周。分别于治疗4周及治疗结束后1周评估2组临床症状及内镜下胃黏膜病变改善率。[结果]:治疗组临床症状缓解率为90.0%,高于对照组(66.7%),2组比较差异有统计学意义(P<0.01);治疗组内镜下黏膜病变缓解率为75.0%,与对照组(68.3%)比较,差异无统计学意义(P>0.05)。[结论]曲昔派特对缓解慢性胃炎主要临床症状的疗效优于迪乐。
[Objective] To observe the curative effect of tranexamic acid on chronic gastritis. [Methods] Patients with chronic gastritis were randomly divided into treatment group and control group, 60 cases each. The treatment group with triamcintelone (100mg / time, tid, taken after meals), the control group with Di music (110mg / time, qid, before meals and before going to bed), two groups were 4 weeks course of treatment. The clinical symptom and endoscopic gastric mucosal lesion improvement rate in two groups were evaluated at 4 weeks after treatment and 1 week after treatment. [Result] The remission rate of clinical symptom in the treatment group was 90.0%, which was higher than that in the control group (66.7%). There was significant difference between the two groups (P <0.01). The response rate of endoscopic mucosal lesion in the treatment group was 75.0% Compared with the control group (68.3%), the difference was not statistically significant (P> 0.05). [Conclusion] Tribendip is superior to diuretic in relieving the main clinical symptoms of chronic gastritis.